Please find below a link to access the new Oruen Round Table. Please be advised that this is for medical professionals.
This is a peer to peer discussion on the role of anticoagulation in the setting of cerebral venous thromboembolism.
- CVT is a rare type of stroke and peripheral venous thromboembolism
- There is scientific evidence supporting anticoagulation in the acute phase of CVT but scant data to guide longer-term oral anticoagulation
- Non-vitamin-K oral anticoagulants (NOACs) are being investigated as an alternative to warfarin in patients with CVT for longer-term management
This discussion’s audience is for the general neurologists and stroke specialists across Europe, once completed, learners will be able to:
- Discuss risk of venous thromboembolism (VTE) after cerebral venous thrombosis (CVT)
- Explain the design of RE-SPECT CVT trial
- Analyse outcomes in RE-SPECT CVT trial
(please note this content is not available for physicians in the UK & US)
Faculty:
José Ferro
Department of Neurosciences and Mental Health
Hospital Santa Maria/Centro Hospitalar Universitário Lisboa Norte
Lisbon, Portugal
Hans-Christoph Diener
Faculty of Medicine
University Duisburg-Essen
Essen, Germany
Jonathan Coutinho
Department of Neurology
Academic Medical Center University of Amsterdam
Amsterdam, The Netherlands
This round table discussion was filmed in Amsterdam by Oruen and was supported by Boehringer Ingelheim.
This discussion has been awarded 1 CME credit by the EACIC; instructions on how to obtain your CME credit will follow at the end of this video.
